An anti-inflammatory tripeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH). Targets gut inflammation and autoimmune pathways with precision.
KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH, retaining the parent hormone's potent anti-inflammatory properties while being small enough for oral bioavailability. It suppresses NF-κB signaling (the master inflammatory transcription factor), reduces pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), and modulates immune cell activation — all without the melanocortin receptor side effects of full alpha-MSH.
IBS is 2x more common in women, and 80% of autoimmune patients are female — making anti-inflammatory peptides disproportionately relevant for women. KPV's oral bioavailability is particularly appealing for women who prefer non-injectable options. Its gut-targeted anti-inflammatory action addresses the intersection of immune dysregulation and digestive dysfunction that many women experience.
KPV is generally well-tolerated in available research. As a naturally derived anti-inflammatory peptide, systemic side effects appear minimal. Oral forms may cause mild GI adjustment symptoms initially. Injectable forms may cause injection site reactions.
Yes — KPV is a tripeptide small enough for oral absorption, which is unusual for peptides. Many practitioners use oral KPV capsules specifically for gut-targeted anti-inflammatory effects.
KPV suppresses NF-κB-driven gut inflammation, which is a key driver of IBS symptoms. While dedicated IBS clinical trials are limited, the anti-inflammatory mechanism is directly relevant to inflammatory bowel conditions.
Part of our Gut & Immune Health hub.
Medical Disclaimer: This profile is for educational purposes only. Always consult a licensed healthcare provider before starting any peptide therapy.
Affiliate Disclosure: Vendor links are affiliate partnerships. Full disclosure →
Take our 60-second quiz for a personalized recommendation.
Find Your Peptide →